Trinity Biotech PLC
TRIB- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0000888721
No open-market purchases or sales by Trinity Biotech PLC insiders were filed in the last 90 days; 20 institutions reported holding it in 13F filings for Q2 2026, worth $388.5K in total; no superinvestor holds it.
13F holders, Q2 2026
Institutional positions in Trinity Biotech PLC as of Jun 30, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 20
- −2 vs. Q1 2026
- Shares held
- 1.02M
- −57.8K (−5.4%) vs. Q1 2026
- Total value
- $388.5K
- −$200.4K (−34.0%) vs. Q1 2026
- New holders
- 2
- 6 more added
- Sold out
- 4
- 4 more reduced
1 institution that held it in Q1 2026 haven't filed for Q2 2026 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q1 2026: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting TRIB on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 20 | $388.5K |
| Q1 2026 | 23 | $588.9K |
| Q4 2025 | 27 | $673.3K |
| Q3 2025 | 28 | $2.81M |
| Q2 2025 | 25 | $1.66M |
| Q1 2025 | 27 | $468.1K |
| Q4 2024 | 23 | $2.30M |
| Q3 2024 | 19 | $2.95M |
| Q2 2024 | 20 | $5.67M |
| Q1 2024 | 19 | $5.97M |
| Q4 2023 | 26 | $2.59M |
| Q3 2023 | 20 | $4.49M |
| Q2 2023 | 20 | $5.93M |
| Q1 2023 | 20 | $5.96M |
| Q4 2022 | 20 | $6.51M |
| Q3 2022 | 21 | $7.50M |
| Q2 2022 | 20 | $8.92M |
| Q1 2022 | 22 | $9.56M |
| Q4 2021 | 21 | $7.74M |
| Q3 2021 | 23 | $11.9M |
| Q2 2021 | 29 | $16.6M |
| Q1 2021 | 34 | $20.3M |
Institutions, Q2 2026
Shares, value and share of portfolio for each institution holding Trinity Biotech PLC; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Hunter Associates Investment Management LLC | 661,210 | $251.0K | 0.03% | +125,000+23.3% | Added |
| Williams & Novak, LLC | 140,543 | $54.6K | 0.04% | +32,900+30.6% | Added |
| Cambridge Investment Research Advisors, Inc. | 44,560 | $18.0K | 0.00% | +22,280+100.0% | Added |
| Susquehanna International Group, LLP | 26,859 | $10.4K | 0.00% | +26,859 | New |
| Moss Adams Wealth Advisors LLC | 25,666 | $9.98K | 0.00% | 00.0% | Unchanged |
| Inspirion Wealth Advisors, LLC | 25,000 | $8.92K | 0.00% | 00.0% | Unchanged |
| Raymond James Financial Inc | 20,319 | $7.90K | 0.00% | 00.0% | Unchanged |
| Becker Capital Management Inc | 18,000 | $7.00K | 0.00% | 00.0% | Unchanged |
| LPL Financial LLC | 17,668 | $6.87K | 0.00% | +2,632+17.5% | Added |
| Geode Capital Management, LLC | 12,598 | $4.90K | 0.00% | −4,044−24.3% | Reduced |
| Rhumbline Advisers | 9,369 | $3.64K | 0.00% | +3,822+68.9% | Added |
| Advisor Group Holdings, Inc. | 3,500 | $1.36K | 0.00% | +3,500 | New |
| Jones Financial Companies LLLP | 3,644 | $1.31K | 0.00% | −160−4.2% | Reduced |
| Wells Fargo & Company | 2,500 | $972 | 0.00% | 00.0% | Unchanged |
| Farther Finance Advisors, LLC | 2,000 | $778 | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 1,107 | $431 | 0.00% | +100+9.9% | Added |
| Morgan Stanley | 400 | $156 | 0.00% | −2−0.5% | Reduced |
| Simplex Trading, LLC | 354 | $137 | 0.00% | −201−36.2% | Reduced |
| Atwood & Palmer Inc | 20 | $8 | 0.00% | 00.0% | Unchanged |
| CoreCap Advisors, LLC | 1 | $0 | 0.00% | 00.0% | Unchanged |
| Yorkville Advisors Global, LP | 0 | $0 | 0.00% | −225,000−100.0% | Sold out |
| Virtu Financial LLC | 0 | $0 | 0.00% | −26,676−100.0% | Sold out |
| Renaissance Technologies LLC | 0 | $0 | 0.00% | −17,762−100.0% | Sold out |
| Triumph Capital Management | 0 | $0 | 0.00% | −1,000−100.0% | Sold out |
| McIlrath & Eck, LLC | – | – | – | – | Not filed |